Patients were given aztreonam (SQ 26,776) 
when possible, during and 1 to 5 days after aztreonam therapy (5 to 9 days after therapy for determination of urinary tract infections). Cases were considered clinically able to be evaluated for safety and efficacy when the patient had received aztreonam for a minimum of 5 days.
Enterococcus was identified by its ability to grow in 6.5% NaCl broth and to hydrolyze esculin in medium containing 40% bile. Enterococcal isolates were not identified. MIC were determined by a microtiter broth dilution technique similar to the one described by Gavin and Barry (1) . Briefly, each bacterial suspension was obtained by inoculating Mueller-Hinton broth with 0.1 ml of an overnight culture, incubating the solution, and adjusting the density of the fresh bacterial suspension with a spectrophotometer to contain 108 CFU/ml. The antimicrobial solutions and their serial twofold dilutions were inoculated (Dynatech MIC-2000) with 0.001 ml of a 1:10 dilution of the bacterial suspension for a final * Corresponding author. concentration of 104 organisms per 0.1 ml. MICs were determined visually after incubation for 24 h at 35°C. The MIC was defined as the lowest concentration of the antibiotic that prevented visible growth.
Superinfection was defined as the development of signs or symptoms of infection during treatment or within the period of posttreatment follow-up, which were due to a pathogen which was not originally present at the subsequently infected site and not recognized as the original causative pathogen. Colonization was defined as the isolation of a significant growth (2105 bacteria for a urinary tract infection) of a previously undetected bacteria at a site in the absence of signs or symptoms of infection at the site.
Cases in which enterococcus was cultured from any body site (even an uninfected site) before therapy were excluded from analysis.
A total of 56 patients were enrolled in the aztreonam treatment protocol. Two patients received aztreonam for less than 4 days, and their cases were excluded from analysis. Nine patients had enterococcus isolated in pretreatment cultures (three urinary tract, three skin, two biliary tree, and one bacteremia). These cases were also excluded frorh further analysis. Two of these patients had enterococcus originally isolated at a site distinct from where it was subsequently cultured. Both patients had skin infections from which enterococcus was isolated. One developed symptomatic urinary tract infection, related to a Foley catheter, which was treated with ampicillin. This patient received no antibiotic concurrently with aztreonam. The second patient developed enterococcal bacteremia on day 23 of aztreonam therapy and was treated with vancomycin. This patient received clindamycin concurrently with aztreonam. Both of these cases were excluded from further analysis because enterococcus was isolated from an initial culture, although the subsequent infection was probably not related to the original enterococcal isolate.
Of 45 of the remaining patients, 8 (17.8%) had enterococcus isolated from cultures during or after aztreonam therapy ( Table 1 ). The MIC of aztreonam was >128 ,ug/ml for all enterococci tested. All eight patients had enterococcus isolated in the urine. Of eight patients, four (50%) required therapy for symptomatic enterococcal urinary tract infection. All four of these patients responded to additional therapy. Four of eight patients were determined to have enterococcal colonization and did not initially require therapy. However, one patient developed enterococcal bacte- It is critical to emphasize that in any clinical situation the distinction must be drawn between colonization and actual infection, lest patients be subjected unnecessarily to additional antimicrobial therapy. Similarly, the clinician should be wary of the fact that colonization may predispose certain individuals to future superinfection (7, 8) .
Previous reports have implicated the broad-spectrum antimicrobial agent moxalactam as being associated with enterococcal superinfection and colonization (2, 10) . Aztreonam has a relatively narrow spectrum of activity as compared with moxalactam, particularly against anaerobic bacteria and gram-positive cocci. It was hoped that the narrower spectrum of this agent would preserve normal colonization resistance preventing such superinfection problems.
However, in the present study, 45 aztreonam treatment courses were complicated by eight cases (17.8%) of enterococcal infection or colonization. In five of the eight cases, additional antimicrobial therapy was required during or after aztreonam therapy for enterococcal superinfection. This represents a considerable risk of enterococcal superinfection (11.1% of all treatment courses). Clinicians using aztreonam alone or in combination with other antimicrobials inactive against enterococcus must be aware of this possible complication of therapy.
